Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brief Summary: This multicenter, double-blind, 2-arm, randomized study will evaluate the efficacy and safety of bevacizumab plus paclitaxel and caboplatin compared with placebo plus paclitaxel and caboplatin in Chinese participants with newly diagnosed, previously untreated Stage III or Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants whose disease has not progressed after six cycles of paclitaxel and carboplatin with either bevacizumab or placebo will continue treatment with either bevacizumab or placebo until disease progression, unacceptable toxicity, or a maximum of 22 cycles, whichever occurs first.


Options:
A: Arm Label: Arm I (paclitaxel and placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo | Arm Label: Arm II (paclitaxel and pazopanib hydrochloride); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Pazopanib Hydrochloride | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (paclitaxel and placebo), Arm II (paclitaxel and pazopanib hydrochloride) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (paclitaxel and placebo), Arm II (paclitaxel and pazopanib hydrochloride) | Intervention Type: DRUG; Name: Pazopanib Hydrochloride; Assigned to Arm(s): Arm II (paclitaxel and pazopanib hydrochloride) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (paclitaxel and placebo)
B: Arm Label: Arm 1: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Niraparib | Arm Label: Arm 2: Niraparib and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Niraparib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2: Niraparib and Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Arm 1: Niraparib, Arm 2: Niraparib and Bevacizumab
C: Arm Label: Bevacizumab + Paclitaxel + Carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Bevacizumab, Drug: Carboplatin | Arm Label: Placebo + Paclitaxel + Carboplatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Bevacizumab + Paclitaxel + Carboplatin, Placebo + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Bevacizumab + Paclitaxel + Carboplatin, Placebo + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Paclitaxel + Carboplatin
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C